Evidence map›Paper›PMID 29422048›Full record

ReviewMalaria journal2018

Tools for surveillance of anti-malarial drug resistance: an assessment of the current landscape.

Christian Nsanzabana, Djibrine Djalle, Philippe J Guérin, Didier Ménard, Iveth J González

Open access · goldAbstract readReview
In one paragraph

Review in Malaria journal, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 51 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
51citing papers in PubMed, 3 pooled it
9.0field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

51 citing papers in PubMed, 3 syntheses or guidelines pooled it, 103 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Trial
  5. IJID regions · 2026
    Review
  6. Article
  7. A review on molecular markers ofJournal of parasitic diseases : official organ of the Indian Society for Parasitology · 2025
    Review
  8. Emergence of chloroquine-sensitiveEmerging microbes & infections · 2025
    Article
  9. Article
  10. Review
  11. Article
  12. Article
  13. Article
  14. Review
  15. Article
  16. Article
  17. Review
  18. Exploring the relationship betweenThe Pan African medical journal · 2024
    Article
  19. A spatio-temporal model of multi-marker antimalarial resistance.Journal of the Royal Society, Interface · 2024
    Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 3 institutions in 3 countries.

Christian NsanzabanaFoundation for Innovative New Diagnostics (FIND), Geneva, Switzerland. nsanzabana.christian@gmail.com.
Djibrine DjalleFoundation for Innovative New Diagnostics (FIND), Geneva, Switzerland.
Philippe J GuérinWorldWide Antimalarial Resistance Network, Oxford, UK.
Didier MénardUnité Biologie des Interactions Hôte-Parasite, Institut Pasteur, Paris, France.
Iveth J GonzálezFoundation for Innovative New Diagnostics (FIND), Geneva, Switzerland.
Foundation for Innovative New Diagnostics · CHInstitut Pasteur · FRWorldwide Veterinary Service · GB

Funding

Department for International Development, UK Government DFID-03Department of Foreign Affairs and Trade, Australian Government AUSCORE-02
6 · The paper itself

Abstract

To limit the spread and impact of anti-malarial drug resistance and react accordingly, surveillance systems able to detect and track in real-time its emergence and spread need to be strengthened or in some places established. Currently, surveillance of anti-malarial drug resistance is done by any of three approaches: (1) in vivo studies to assess the efficacy of drugs in patients; (2) in vitro/ex vivo studies to evaluate parasite susceptibility to the drugs; and/or (3) molecular assays to detect validated gene mutations and/or gene copy number changes that are associated with drug resistance. These methods are complementary, as they evaluate different aspects of resistance; however, standardization of methods, especially for in vitro/ex vivo and molecular techniques, is lacking. The World Health Organization has developed a standard protocol for evaluating the efficacy of anti-malarial drugs, which is used by National Malaria Control Programmes to conduct their therapeutic efficacy studies. Regional networks, such as the East African Network for Monitoring Antimalarial Treatment and the Amazon Network for the Surveillance of Antimalarial Drug Resistance, have been set up to strengthen regional capacities for monitoring anti-malarial drug resistance. The Worldwide Antimalarial Resistance Network has been established to collate and provide global spatial and temporal trends information on the efficacy of anti-malarial drugs and resistance. While exchange of information across endemic countries is essential for monitoring anti-malarial resistance, sustainable funding for the surveillance and networking activities remains challenging. The technology landscape for molecular assays is progressing quite rapidly, and easy-to-use and affordable new techniques are becoming available. They also offer the advantage of high throughput analysis from a simple blood spots obtained from a finger prick. New technologies combined with the strengthening of national reference laboratories in malaria-endemic countries through standardized protocols and training plus the availability of a proficiency testing programme, would contribute to the improvement and sustainability of anti-malarial resistance surveillance networks worldwide.

Indexed as

Drug ResistanceAntimalarialsMalaria, FalciparumParasitic Sensitivity TestsPlasmodium falciparumAntimalarialsAntimalarialDrugLandscapeMarkersMolecularPlasmodium falciparumResistanceSurveillance

Identifiers

PMID29422048
PMCPMC5806256
OpenAlexW2786619358

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.